SuperworthRevolution Medicines RVMD
- Market cap
- $40.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- a loss over the last year
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −3.1%
Revolution Medicines' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $742K−95% | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $107.7M+55% | $148.5M+125% | $118M+71% | $134.9M+38% | $151.8M+41% | $188.1M+27% | $205.7M+74% | $224.1M+66% | $262.5M+73% | $294.9M+57% | $344M+67% | $394.9M+76% |
| SG&A | $15.5M+49% | $32.2M+196% | $22.8M+73% | $21.7M+48% | $24M+55% | $28.2M−13% | $35M+53% | $40.6M+87% | $52.8M+120% | $66.7M+136% | $101.3M+189% | $110.2M+172% |
| −$123.2M+61% | −$180M+192% | −$140.9M+87% | −$156.6M+44% | −$175.7M+43% | −$216.3M+20% | −$240.8M+71% | −$264.7M+69% | −$315.3M+79% | −$361.6M+67% | −$445.2M+85% | −$505.1M+91% | |
| Interest expense | n/a | n/a | n/a | n/a | $0 | $0 | $0 | $867K | $11.4M | $11.9M | $12.2M | $23.8M+2643% |
| Pre-tax income | −$112.3M+53% | −$161.2M+185% | −$116M+70% | −$133.2M+36% | −$156.3M+39% | −$195.3M+21% | −$213.4M+84% | −$247.8M+86% | −$305.2M+95% | −$364.9M+87% | −$453.8M+113% | −$644.4M+160% |
| −$3.9M+1202% | $343K | $0 | $0 | $0 | −$753K | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$108.4M+48% | −$161.5M+186% | −$116M+70% | −$133.2M+36% | −$156.3M+44% | −$194.6M+20% | −$213.4M+84% | −$247.8M+86% | −$305.2M+95% | −$364.9M+88% | −$453.8M+113% | −$644.4M+160% |
| −$0.99+14% | −$1.14+81% | −$0.70−3% | −$0.81−12% | −$0.94−5% | −$1.12−2% | −$1.13+61% | −$1.31+62% | −$1.61+71% | −$1.88+68% | −$2.29+103% | −$3.06+134% | |
| 109.2M+29% | 141.2M+58% | 164.7M+74% | 165.1M+55% | 166.8M+53% | 174.2M+23% | 188.1M+14% | 188.6M+14% | 189.2M+13% | 194.5M+12% | 198.1M+5% | 210.9M+12% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $25.6M | $7.3M to $66.2M | −$2.35 | −$2.51 to −$2.07 | 16 |
| Q4 FY26 | $184M | $66.8M to $436.1M | −$1.90 | −$2.69 to −$1.00 | 15 |
| Q1 FY27 | $216M | $66.4M to $449.1M | −$1.82 | −$4.38 to −$0.18 | 6 |
| Q2 FY27 | $250.9M | $77.2M to $521.7M | −$1.72 | −$4.13 to −$0.17 | 6 |
| Q3 FY27 | $306.1M | $94.1M to $636.4M | −$1.57 | −$3.77 to −$0.16 | 6 |
| Q4 FY27 | $401.1M | $123.4M to $833.8M | −$1.37 | −$3.29 to −$0.14 | 6 |
| Q1 FY28 | $400M | $123M to $831.6M | −$1.56 | −$3.75 to −$0.16 | 14 |
| Q2 FY28 | $450M | $138.4M to $935.6M | −$1.44 | −$3.46 to −$0.14 | 14 |
Peers
Companies in Biotechnology nearest Revolution Medicines' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RVMDRevolution Medicines | $40.1B | n/m | n/a | n/m | n/m | n/m | n/m |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| VRTXVertex Pharmaceuticals | $132.8B | 30.5× | 28.6× | 27.0× | 10.6× | +10% | 35.0% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| Peer median | $24.3B | 25.8× | 32.8× | 26.8× | 6.8× | +19% | 26.3% |
Investors who own it
Investors we follow who held Revolution Medicines at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office1.7% of portfolioadded
- Baillie GiffordBaillie Gifford0.0% of portfolioadded
- Ron BaronBaron Capital0.0% of portfolioadded
More on Revolution Medicines
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .